Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | PARK7 | Q99497 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | ALDH2 | P05091 | 7/20 | 0.60 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736331 | 0.86 | PARK7 (0.75) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL28070671 | 0.81 | TP53 (0.76) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL4734658 | 0.78 | PARK7 (0.72) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL4736390 | 0.78 | PARK7 (1.00) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL27881830 | 0.77 | ALDH1A1 (0.64) | PARK7ALDH1A1ALDH2ALDH3A1CASP3 | |
| SCHEMBL4739092 | 0.75 | PARK7 (0.82) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL30774299 | 0.75 | PARK7 (0.82) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL5659265 | 0.75 | ALDH1A1 (1.00) | ALDH1A1ALDH2ALDH3A1CASP3CHRM5 | |
| SCHEMBL20874420 | 0.75 | PARK7 (0.80) | TP53MAPTPARK7ALDH1A1ALDH2 | |
| SCHEMBL19297704 | 0.73 | ALDH1A1 (0.62) | TP53MAPTPARK7ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | TP53 662/4885MAPT 3443/4885PARK7 1455/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | TP53 662/4885MAPT 3443/4885PARK7 1455/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | TP53 662/4885MAPT 3443/4885PARK7 1455/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | TP53 662/4885MAPT 3443/4885PARK7 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.